Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02560805 · ClinicalTrials.gov registry record · Phase 2

Role of Sympathetic Overactivity and Angiotensin II in PTSD and CV

A Phase 2 study, sponsored by Emory University.

Recruiting
Registry status
Phase 2
Development phase
134
Enrollment target

NCT02560805: Recruiting Phase 2 study, sponsored by Emory University.

NCT02560805 is a Phase 2 study that is actively recruiting participants, run by Emory University. The registered enrollment target is 134 participants, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02560805, a Phase 2 study, is actively recruiting participants, sponsored by Emory University.

RECRUITING
Registry status
Phase 2
Development phase
134 participants
Enrollment target

Study Summary

The purpose of this study is to find out why patients with post-traumatic stress disorder (PTSD) have an increased risk for heart disease and high blood pressure later in life. A second purpose is to find out what causes PTSD patients to have high adrenaline levels during stress. This study will also test if a medicine called losartan improves high adrenaline levels in patients with PTSD and if a certain gene that has to do with high blood pressure might be associated with high adrenaline levels.

Primary Outcome

Multiunit postganglionic sympathetic nerve activity is recorded from a tungsten microelectrode inserted into the peroneal nerve with a reference microelectrode inserted in close proximity. Efferent nerve signals are amplified, filtered, rectified and integrated (time constant 0.1 s) to obtain a mean voltage display of MSNA. MSNA bursts are automatically detected using the following criteria: burst-to-noise ratio of 3:1 within a 0.5-s search window, with an average latency of 1.2-1.3 s in burst o

Interventions

  • PROCEDURE Microneurography
  • BEHAVIORAL Combat virtual reality video clip
  • PROCEDURE Handgrip Exercise
  • PROCEDURE Cold Pressor Test (CPT)
  • DRUG Sodium Nitroprusside (SNP)

Trial Details

FieldValue
Enrollment Target 134 participants
Start Date 2015-10
Est. Completion 2027-03-30
Phase Phase 2
Emory University

1,208 total trials

What NCT02560805 shows while recruiting

NCT02560805 is an interventional study that assigns participants to a tested intervention. The registered 134 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target.

The record links to 0 conditions, and to 5 interventions - of which Microneurography is the first listed.

NCT02560805 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02560805 about?

NCT02560805 is a clinical study titled "Role of Sympathetic Overactivity and Angiotensin II in PTSD and CV". The purpose of this study is to find out why patients with post-traumatic stress disorder (PTSD) have an increased risk for heart disease and high blood pressure later in life. A second purpose is to find out what causes PTSD patients to have high adrenaline levels during stress. This study will als...

What is the current status of trial NCT02560805?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 134 participants. The study started on 2015-10. Estimated completion is 2027-03-30.

What interventions are being tested in trial NCT02560805?

The interventions under investigation include: Microneurography (PROCEDURE), Combat virtual reality video clip (BEHAVIORAL), Handgrip Exercise (PROCEDURE), Cold Pressor Test (CPT) (PROCEDURE), Sodium Nitroprusside (SNP) (DRUG).

Who is sponsoring clinical trial NCT02560805?

This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02560805's enrollment target sits among peer trials

134 537th of 2000 higher than 1,463 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02469662 · 134 participants · NA

    Clinical Outcomes Study of the Nexel Total Elbow

  • NCT03110822 · 134 participants · Phase 1

    A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients

  • NCT04678648 · 134 participants · Phase 1

    A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies

  • NCT05264857 · 134 participants · NA

    Decision Aid and Thyroid Nodules Management

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02560805, the US trial registry maintained by the National Library of Medicine. NCT02560805 (mid enrollment · none site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.